These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 33734167)
1. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). Suzuki K; Castelli M; Komaroff M; Starling B; Terahara T; Citrome L J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):286-294. PubMed ID: 33734167 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study. Citrome L; Walling DP; Zeni CM; Starling BR; Terahara T; Kuriki M; Park AS; Komaroff M J Clin Psychiatry; 2020 Dec; 82(1):. PubMed ID: 33326711 [TBL] [Abstract][Full Text] [Related]
3. Asenapine pharmacokinetics and tolerability in a pediatric population. Dogterom P; Riesenberg R; de Greef R; Dennie J; Johnson M; Pilla Reddy V; Miltenburg AM; Findling RL; Jakate A; Carrothers TJ; Troyer MD Drug Des Devel Ther; 2018; 12():2677-2693. PubMed ID: 30214156 [TBL] [Abstract][Full Text] [Related]
4. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Gerrits M; de Greef R; Peeters P Biopharm Drug Dispos; 2010 Jul; 31(5-6):351-7. PubMed ID: 20549835 [TBL] [Abstract][Full Text] [Related]
5. Asenapine Transdermal Patch for the Management of Schizophrenia. Zhou M; Derakhshanian S; Rath A; Bertrand S; DeGraw C; Barlow R; Menard A; Kaye AM; Hasoon J; Cornett EM; Kaye AD; Viswanath O; Urits I Psychopharmacol Bull; 2020 Sep; 50(4):60-82. PubMed ID: 33012873 [TBL] [Abstract][Full Text] [Related]
6. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. Gerrits MG; de Greef R; Dogterom P; Peeters PA J Clin Pharmacol; 2012 May; 52(5):757-65. PubMed ID: 21628604 [TBL] [Abstract][Full Text] [Related]
7. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia. El-Tokhy FS; Abdel-Mottaleb MMA; El-Ghany EA; Geneidi AS Int J Pharm; 2021 Oct; 608():121080. PubMed ID: 34506923 [TBL] [Abstract][Full Text] [Related]
8. The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers. Dogterom P; de Greef R; Peeters PA Eur J Clin Pharmacol; 2015 Jan; 71(1):65-74. PubMed ID: 25552402 [TBL] [Abstract][Full Text] [Related]
9. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Citrome L Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study. Parikh N; Goskonda V; Chavan A; Dillaha L Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506 [TBL] [Abstract][Full Text] [Related]
13. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Elshoff JP; Braun M; Andreas JO; Middle M; Cawello W Clin Ther; 2012 Apr; 34(4):966-78. PubMed ID: 22401642 [TBL] [Abstract][Full Text] [Related]
14. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. Walling DP; Hassman HA; Anta L; Ochoa L; Ayani I; Martínez J; Gutierro I Drug Des Devel Ther; 2021; 15():4371-4382. PubMed ID: 34703212 [TBL] [Abstract][Full Text] [Related]
15. Development and Optimization of Asenapine Sublingual Film Using QbD Approach. Dalal R; Shah J; Gorain B; Choudhury H; Jacob S; Mehta TA; Shah H; Nair AB AAPS PharmSciTech; 2021 Oct; 22(7):244. PubMed ID: 34608546 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P Clin Drug Investig; 2009; 29(2):87-100. PubMed ID: 19133704 [TBL] [Abstract][Full Text] [Related]
17. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Dubovsky SL; Frobose C; Phiri P; de Greef R; Panagides J Int J Geriatr Psychiatry; 2012 May; 27(5):472-82. PubMed ID: 21755540 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375 [TBL] [Abstract][Full Text] [Related]
19. Asenapine: an atypical antipsychotic with atypical formulations. Musselman M; Faden J; Citrome L Ther Adv Psychopharmacol; 2021; 11():20451253211035269. PubMed ID: 34540197 [TBL] [Abstract][Full Text] [Related]